Neogenomics (NEO) PT Lowered to $29 at Needham & Company
Tweet Send to a Friend
Needham & Company analyst Mike Matson lowered the price target on Neogenomics (NASDAQ: NEO) to $29.00 (from $41.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
